中国神经再生研究(英文版) ›› 2022, Vol. 17 ›› Issue (12): 2637-2642.doi: 10.4103/1673-5374.336137

• 综述:退行性病与再生 • 上一篇    下一篇

帕金森病的内源性与外源性细胞替代:我们在哪里,我们要去哪里?

  

  • 出版日期:2022-12-15 发布日期:2022-05-05

Endogenous versus exogenous cell replacement for Parkinson’s disease: where are we at and where are we going?

Theodora Mourtzi*, Ilias Kazanis§   

  1. Laboratory of Developmental Biology, Department of Biology, University of Patras, Patras, Greece
    §Senior author.
  • Online:2022-12-15 Published:2022-05-05
  • Contact: Theodora Mourtzi, PhD, mourtzi@upatras.gr.

摘要: https://orcid.org/0000-0001-5106-8214 (Theodora Mourtzi)

Abstract: Parkinson’s disease is the second most common neurodegenerative disease and has currently no effective treatment, one that would be able to stop or reverse the loss of dopaminergic neurons in the substantia nigra pars compacta. In addition, Parkinson’s disease diagnosis is typically done when a significant percentage of the dopaminergic neurons is already lost. In neurodegenerative disorders, some therapeutic strategies could be effective only at inhibiting further degeneration; on the other hand, cell replacement therapies aim at replacing lost neurons, an approach that would be ideal for the treatment of Parkinson’s disease. Many cell replacement therapies have been tested since the 1970s in the field of Parkinson’s disease; however, there are still significant limitations prohibiting a successful clinical application. From the first fetal midbrain intrastriatal graft to the most recent conversion of astrocytes into dopaminergic neurons, we have gained equally, significant insights and questions still looking for an answer. This review aims to summarize the main milestones in cell replacement approaches against Parkinson’s disease. By focusing on achievements and failures, as well as on the additional research steps needed, we aim to provide perspective on how future cell replacement therapies treats Parkinson’s disease.

Key words: endogenous, neurodegenerative disease, neurogenesis, neurotrophic factors, Parkinson’s disease, stem cells, transdifferentiation, transplantations